Non-invasive monitoring of the therapeutic response in sorafenib-treated hepatocellular carcinoma based on photoacoustic imaging
暂无分享,去创建一个
Jae Hwan Lee | Joon Koo Han | Seunghyun Lee | J. Han | J. H. Kim | Seunghyun Lee | Jeong Hwa Lee | Jung Hoon Kim | Jae Hwan Lee | Jeong Hwa Lee
[1] Tayyaba Hasan,et al. Prediction of Tumor Recurrence and Therapy Monitoring Using Ultrasound-Guided Photoacoustic Imaging , 2015, Theranostics.
[2] S. Påhlman,et al. Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer. , 2016, Pharmacology & therapeutics.
[3] N. Tamaki,et al. Dual tracer evaluation of dynamic changes in intratumoral hypoxic and proliferative states after radiotherapy of human head and neck cancer xenografts using radiolabeled FMISO and FLT , 2014, BMC Cancer.
[4] Jianxiang Wang,et al. Suppression of orthotopically implanted hepatocarcinoma in mice by umbilical cord-derived mesenchymal stem cells with sTRAIL gene expression driven by AFP promoter. , 2014, Biomaterials.
[5] A. Harris,et al. Metabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentiality , 2015, EMBO molecular medicine.
[6] Jan Laufer,et al. Quantitative spatially resolved measurement of tissue chromophore concentrations using photoacoustic spectroscopy: application to the measurement of blood oxygenation and haemoglobin concentration , 2007, Physics in medicine and biology.
[7] Jun Wang,et al. Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[8] H. Moon,et al. Hypoxia-induced angiogenesis in human hepatocellular carcinoma , 2002, Journal of Molecular Medicine.
[9] M. Welker,et al. Anti-angiogenesis in hepatocellular carcinoma treatment: current evidence and future perspectives. , 2011, World journal of gastroenterology.
[10] Moustapha Hassan,et al. Real-Time Assessment of Tissue Hypoxia In Vivo with Combined Photoacoustics and High-Frequency Ultrasound , 2014, Theranostics.
[11] B. Kholodenko,et al. Evaluating Strategies to Normalise Biological Replicates of Western Blot Data , 2014, PloS one.
[12] Wenxin Qin,et al. Hypoxia upregulates Rab11-family interacting protein 4 through HIF-1α to promote the metastasis of hepatocellular carcinoma , 2015, Oncogene.
[13] N. Weidner. Intratumor microvessel density as a prognostic factor in cancer. , 1995, The American journal of pathology.
[14] Liang Zhao,et al. MiR-338-3p Inhibits Hepatocarcinoma Cells and Sensitizes These Cells to Sorafenib by Targeting Hypoxia-Induced Factor 1α , 2014, PloS one.
[15] N. Tamaki,et al. Evaluation of changes in the tumor microenvironment after sorafenib therapy by sequential histology and 18F-fluoromisonidazole hypoxia imaging in renal cell carcinoma , 2012, International journal of oncology.
[16] R. Wenger,et al. The hypoxia-inducible factor-1α is a negative factor for tumor therapy , 2003, Oncogene.
[17] Baorui Liu,et al. Hypoxia-specific ultrasensitive detection of tumours and cancer cells in vivo , 2015, Nature Communications.
[18] S. Wilhelm,et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer , 2007, Nature Reviews Drug Discovery.
[19] Dieter Häussinger,et al. Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.
[20] H. Eguchi,et al. Role of the Hypoxia-Related Gene, JMJD1A, in Hepatocellular Carcinoma: Clinical Impact on Recurrence after Hepatic Resection , 2012, Annals of Surgical Oncology.
[21] B. Krock,et al. Hypoxia-induced angiogenesis: good and evil. , 2011, Genes & cancer.
[22] R. Jain,et al. Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal‐derived factor 1 alpha/C‐X‐C receptor type 4 axis and myeloid differentiation antigen–positive myeloid cell infiltration in mice , 2014, Hepatology.
[23] A. le Pape,et al. High Resolution Ultrasound and Photoacoustic Imaging of Orthotopic Lung Cancer in Mice: New Perspectives for Onco-Pharmacology , 2016, PloS one.
[24] A. Mousa,et al. Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma , 2008, Saudi Journal of Gastroenterology : Official Journal of the Saudi Gastroenterology Association.
[25] G. Semenza. Hypoxia and cancer , 2007, Cancer and Metastasis Reviews.
[26] Wei Zheng,et al. Antiangiogenic tumor treatment: noninvasive monitoring with contrast pulse sequence imaging for contrast-enhanced grayscale ultrasound. , 2010, Academic radiology.
[27] V. Goh,et al. Molecular imaging of hypoxia in non-small-cell lung cancer , 2015, European Journal of Nuclear Medicine and Molecular Imaging.
[28] L. Rich,et al. Photoacoustic imaging of vascular hemodynamics: validation with blood oxygenation level-dependent MR imaging. , 2015, Radiology.
[29] Y. Imai,et al. Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast‐enhanced US , 2013, Liver international : official journal of the International Association for the Study of the Liver.
[30] G. Chen,et al. Sorafenib Inhibits Hypoxia-Inducible Factor-1α Synthesis: Implications for Antiangiogenic Activity in Hepatocellular Carcinoma , 2012, Clinical Cancer Research.
[31] A. Needles,et al. Development and initial application of a fully integrated photoacoustic micro-ultrasound system , 2013, IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control.
[32] D. Auclair,et al. BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.
[33] P. Beard. Biomedical photoacoustic imaging , 2011, Interface Focus.
[34] Zhao-You Tang,et al. Angiogenesis in hepatocellular carcinoma: the retrospectives and perspectives , 2004, Journal of Cancer Research and Clinical Oncology.
[35] Xuehua Xu,et al. Effect of hypoxia inducible factor-1 antisense oligonucleotide on liver cancer. , 2015, International journal of clinical and experimental medicine.
[36] Y. Urano,et al. Photoacoustic Tomography of Human Hepatic Malignancies Using Intraoperative Indocyanine Green Fluorescence Imaging , 2014, PloS one.
[37] S. Wilhelm,et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models , 2007, Cancer Chemotherapy and Pharmacology.
[38] J. Miyazaki,et al. Electroporation-mediated interleukin-12 gene therapy for hepatocellular carcinoma in the mice model. , 2001, Cancer research.
[39] Ying-jian Liang,et al. Hypoxia‐mediated sorafenib resistance can be overcome by EF24 through Von Hippel‐Lindau tumor suppressor‐dependent HIF‐1α inhibition in hepatocellular carcinoma , 2013, Hepatology.
[40] 山下 洋市. Electroporation-mediated interleukin-12 gene therapy for hepatocellular carcinoma in the mice model , 2002 .
[41] R. Wenger,et al. The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. , 2003, Oncogene.
[42] B. Zhai,et al. Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma. , 2013, World journal of hepatology.
[43] R. Coffey,et al. Volume of Preclinical Xenograft Tumors Is More Accurately Assessed by Ultrasound Imaging Than Manual Caliper Measurements , 2010, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.
[44] M. Yoshimura,et al. Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels , 2012, Nature Communications.
[45] A. Taketomi. Clinical trials of antiangiogenic therapy for hepatocellular carcinoma , 2016, International Journal of Clinical Oncology.
[46] M. Mejías,et al. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats , 2009, Hepatology.